Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Position Cut by Sei Investments Co.

Sei Investments Co. decreased its position in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) by 30.0% in the 4th quarter, HoldingsChannel.com reports. The fund owned 24,568 shares of the company’s stock after selling 10,510 shares during the quarter. Sei Investments Co.’s holdings in Protagonist Therapeutics were worth $948,000 as of its most recent filing with the SEC.

Other institutional investors have also modified their holdings of the company. Franklin Resources Inc. boosted its stake in Protagonist Therapeutics by 127.2% during the 3rd quarter. Franklin Resources Inc. now owns 81,591 shares of the company’s stock valued at $3,782,000 after purchasing an additional 45,674 shares during the period. Principal Financial Group Inc. increased its stake in shares of Protagonist Therapeutics by 3,099.4% in the third quarter. Principal Financial Group Inc. now owns 320,832 shares of the company’s stock valued at $14,437,000 after purchasing an additional 310,804 shares during the period. Assenagon Asset Management S.A. bought a new stake in shares of Protagonist Therapeutics during the fourth quarter valued at approximately $2,016,000. Charles Schwab Investment Management Inc. boosted its position in shares of Protagonist Therapeutics by 2.3% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 578,409 shares of the company’s stock worth $22,327,000 after buying an additional 12,906 shares during the period. Finally, Barclays PLC grew its holdings in Protagonist Therapeutics by 223.6% in the 3rd quarter. Barclays PLC now owns 126,995 shares of the company’s stock worth $5,714,000 after buying an additional 87,755 shares in the last quarter. Institutional investors own 98.63% of the company’s stock.

Protagonist Therapeutics Trading Down 2.8 %

Shares of Protagonist Therapeutics stock opened at $43.21 on Tuesday. Protagonist Therapeutics, Inc. has a 52 week low of $24.22 and a 52 week high of $60.60. The company’s 50-day moving average price is $43.58 and its two-hundred day moving average price is $42.89. The stock has a market cap of $2.65 billion, a PE ratio of 16.24 and a beta of 2.30.

Protagonist Therapeutics (NASDAQ:PTGX) last released its earnings results on Friday, February 21st. The company reported $1.98 EPS for the quarter, topping analysts’ consensus estimates of ($0.09) by $2.07. The business had revenue of $170.64 million for the quarter, compared to the consensus estimate of $56.65 million. Protagonist Therapeutics had a net margin of 52.76% and a return on equity of 34.68%. On average, equities analysts predict that Protagonist Therapeutics, Inc. will post 2.43 EPS for the current fiscal year.

Analysts Set New Price Targets

PTGX has been the topic of several recent analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $54.00 target price on shares of Protagonist Therapeutics in a research note on Monday, March 10th. Wedbush restated an “outperform” rating and set a $70.00 price objective on shares of Protagonist Therapeutics in a research note on Friday, March 28th. BTIG Research set a $73.00 price objective on shares of Protagonist Therapeutics in a report on Monday, March 3rd. JPMorgan Chase & Co. raised their target price on shares of Protagonist Therapeutics from $53.00 to $57.00 and gave the company an “overweight” rating in a research note on Tuesday, March 4th. Finally, BMO Capital Markets upped their price target on shares of Protagonist Therapeutics from $62.00 to $72.00 and gave the stock an “outperform” rating in a research note on Tuesday, March 11th. Two investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Protagonist Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $62.56.

Insider Buying and Selling at Protagonist Therapeutics

In other Protagonist Therapeutics news, insider Arturo Md Molina sold 30,514 shares of the company’s stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $55.74, for a total transaction of $1,700,850.36. Following the completion of the sale, the insider now directly owns 83,892 shares of the company’s stock, valued at approximately $4,676,140.08. This represents a 26.67 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director William D. Waddill sold 4,000 shares of Protagonist Therapeutics stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $54.25, for a total transaction of $217,000.00. Following the completion of the transaction, the director now directly owns 13,130 shares in the company, valued at approximately $712,302.50. This trade represents a 23.35 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 64,776 shares of company stock valued at $3,585,010. Corporate insiders own 5.40% of the company’s stock.

About Protagonist Therapeutics

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.